Abstract
BackgroundiACT interventions can be cost-effective and convenient for providing evidence-based care to breast cancer patients (BCPs). ObjectivesDetermining the feasibility, acceptability, and efficacy of Oncovox, a guided iACT intervention designed to improve psychosocial outcomes in BCP undergoing treatment. MethodsA parallel, two-arm, open-label, randomized controlled trial (RCT) evaluating an 8-module intervention. Participants were randomized to the iACT group (N = 75) or a waitlist group (N = 75). Primary outcomes: Quality of Life (QoL), Behavioral Activation (BA), Symptom Interference (SI) and Reward Noticing (RN). Secondary outcomes: anxiety and depression symptoms and psychological flexibility (PF). Measurements were made pre- and post-intervention, twice during the intervention, and at 1- and 2-month follow-up. ResultsSI, anxiety and depression, and PF improved significantly, with further improvement at follow-up. QoL, BA and RN improved moderately, but only when imputed data were analyzed. ConclusionsOncovox has good dissemination potential and could be appropriately implemented in stepped care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
